Security key
09061G101
BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN)
CUSIP: 09061G101
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 192,632,743
- Total 13F shares
- 184,517,274
- Share change
- +3,144,568
- Total reported value
- $10,145,314,583
- Put/Call ratio
- 83%
- Price per share
- $54.97
- Number of holders
- 576
- Value change
- +$90,429,124
- Number of buys
- 324
- Number of sells
- 260
Report period
Q2 2025
Institutions
576
Top holders
10
BMRN full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
BIOMARIN PHARMACEUTICAL INC SEC filings
BIOMARIN PHARMACEUTICAL INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09061G101
Recent filing periods:
Top shareholders of BMRN - BIOMARIN PHARMACEUTICAL INC - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ |
13F
13D/G
|
Company |
8.2%
from 13D/G
|
17,773,281
|
$1,256,393,234 | — | 31 Mar 2025 | |
| Capital Research Global Investors |
13F
13D/G
|
Company |
4.8%
from 13D/G
|
9,150,655
|
$646,859,812 | — | 31 Mar 2025 | |
| Robert J. Hombach |
3/4/5
|
Director |
0.02%
|
41,870
|
$2,636,972 | — | 20 May 2025 | |
| Willard H. Dere |
3/4/5
|
Director |
0.02%
|
38,950
|
$2,453,071 | — | 20 May 2025 | |
| Elizabeth M. Anderson |
3/4/5
|
Director |
0.02%
|
34,450
|
$2,169,661 | — | 20 May 2025 | |
| Maykin Ho |
3/4/5
|
Director |
0.01%
|
28,010
|
$1,764,069 | — | 20 May 2025 | |
| Barbara W. Bodem |
3/4/5
|
Director |
0.01%
|
13,555
|
$853,693 | — | 20 May 2025 | |
| Athena Countouriotis |
3/4/5
|
Director |
0.01%
|
13,550
|
$853,379 | — | 20 May 2025 | |
| Mark J. Enyedy |
3/4/5
|
Director |
0.01%
|
13,550
|
$853,379 | — | 20 May 2025 | |
| Timothy P. Walbert |
3/4/5
|
Director |
0.01%
|
10,196
|
$642,143 | — | 20 May 2025 | |
| BlackRock, Inc. |
13F
|
Company |
12%
|
23,778,999
|
$1,680,937,387 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
9.9%
|
19,003,212
|
$1,343,337,056 | — | 31 Mar 2025 | |
| DODGE & COX |
13F
|
Company |
7.8%
|
14,955,240
|
$1,057,185,916 | — | 31 Mar 2025 | |
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
5.6%
|
10,800,059
|
$763,456,171 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
4.4%
|
8,463,090
|
$598,255,832 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
2.2%
|
4,207,563
|
$297,422,307 | — | 31 Mar 2025 | |
| Elliott Investment Management L.P. |
13F
|
Company |
1.8%
|
3,500,338
|
$247,438,893 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
3,431,253
|
$242,024,845 | — | 31 Mar 2025 | |
| NORGES BANK |
13F
|
Company |
1.7%
|
3,308,385
|
$233,869,736 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.5%
|
2,925,805
|
$203,987,099 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
1.4%
|
2,609,639
|
$46,950,181 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.98%
|
1,887,353
|
$133,416,984 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.88%
|
1,696,864
|
$119,951,318 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.88%
|
1,694,014
|
$119,749,850 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.83%
|
1,595,058
|
$112,754,650 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.83%
|
1,592,963
|
$112,606,555 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.8%
|
1,532,314
|
$108,319,277 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.72%
|
1,388,728
|
$98,169,182 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.72%
|
1,378,564
|
$97,450,679 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.63%
|
1,217,146
|
$86,040,051 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.61%
|
1,167,495
|
$82,535,862 | — | 31 Mar 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.56%
|
1,079,304
|
$76,296,000 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.55%
|
1,064,924
|
$75,279,478 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.54%
|
1,042,885
|
$73,721,727 | — | 31 Mar 2025 | |
| DnB Asset Management AS |
13F
|
Company |
0.51%
|
991,486
|
$70,088,145 | — | 31 Mar 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
0.51%
|
991,207
|
$70,068,423 | — | 31 Mar 2025 | |
| Legal & General Group Plc |
13F
|
Company |
0.48%
|
927,683
|
$65,577,912 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.47%
|
895,771
|
$63,322,052 | — | 31 Mar 2025 | |
| FULLER & THALER ASSET MANAGEMENT, INC. |
13F
|
Company |
0.43%
|
836,397
|
$59,124,893 | — | 31 Mar 2025 | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM |
13F
|
Company |
0.43%
|
835,795
|
$59,082,349 | — | 31 Mar 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.42%
|
809,122
|
$57,196,834 | — | 31 Mar 2025 | |
| Man Group plc |
13F
|
Company |
0.42%
|
804,294
|
$56,855,543 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.39%
|
759,388
|
$53,681,138 | — | 31 Mar 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.39%
|
755,275
|
$53,390,389 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.38%
|
733,468
|
$51,848,819 | — | 31 Mar 2025 | |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ |
13F
|
Company |
0.37%
|
715,049
|
$50,546,814 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.35%
|
675,272
|
$47,734,978 | — | 31 Mar 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.35%
|
669,481
|
$47,325,628 | — | 31 Mar 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.32%
|
607,862
|
$42,969,765 | — | 31 Mar 2025 | |
| THRIVENT FINANCIAL FOR LUTHERANS |
13F
|
Company |
0.31%
|
605,622
|
$42,812,000 | — | 31 Mar 2025 |
Institutional Holders of BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN) as of Q2 2025
As of 30 Jun 2025,
BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN) was held by
576 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
184,517,274 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, PRIMECAP MANAGEMENT CO/CA/, Dodge & Cox, VIKING GLOBAL INVESTORS LP, STATE STREET CORP, AQR CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, and MORGAN STANLEY.
This page lists
579
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
576
Q2 2025 holders
576
Holder diff
0
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.